Sarilumab is an interleukin-6 receptor antagonist indicated, in Canada, for rheumatoid arthritis and has been identified as a potential option for treating COVID-19. Two published studies were identified in the CADTH Horizon Scan that evaluated the efficacy and safety of sarilumab for the treatment of COVID-19.
Link to Report
Was this site helpful?
If you couldn’t find what you are looking for, please submit a request.